

Workshop 'Novel Tools for Early Detection of Pancreatic Cancer' 06 - 07 July 2012 at the Hotel Bristol, Bonn, Germany

Preliminary Programme

15.00 Arrivals, Welcome

Session 1: "Intro 15.30 - 16.10	
16.10 - 16.50	2. Tumor microenvironment: impact for early lesion progression Irene Esposito, Munich
16.50 - 17.10	Coffee Break
17.10 - 17.30	3. Familial Pancreatic Cancer Screening and Consequences Detlef Bartsch, Marburg
17.30 - 18.10	 What do we learn from pancreatic cancer genome sequencing to help the patient? Andrew Biankin, Sydney
18.10 - 18.50	 Cystic Precursor Lesions of Pancreatic Cancer: A paradigm for early detection of pancreatic neoplasma Anirban Maitra, Baltimore

Saturday, 07 July 2012

19.30

09.00	Welcome

Session 2: Biomarker

09.10 - 09.50	6.	What (will be) are the requirements for a biomarker to detect early
		pancreatic cancer? What are the risk groups amenable for biomarker
		screening?

John Neoptolemos, Liverpool

Get Together / Dinner

09.50 - 10.30	7. Using molecular markers to improve the accuracy of pancreatic screening
	Michael Goggins, Baltimore

10.30 - 10.50

10.50 - 11.30 8. Is multiplexed serum markers screening the key for early detection of pancreatic cancer?

Anna E. Lokshin, Pittsburgh

11.30 - 12.10 9. Immune infiltrates as predictive markers in pancreatic cancer Maria Pia Protti, Milano

12.10 - 13.00 LUNCH

Draft, status: 16.02.2012



Discussion Forum

All speakers and workshop participants

Session 3: Imaging

13.00 - 13.40	10. Future and presence of molecular imaging Jan Grimm, New York
13.40 - 14.20	11. New directions in PET imaging Jason S Lewis, New York
14.20 - 15.00	12. Nature's derived nanoparticles for targeted diagnosis and therapy William Mulder, New York
15.00 - 15.15	Coffee Break

Session 4: Endoscopy

15.15 - 16.00

16.00 - 16.20	13. Biomarker discovery in mouse and human pancreatic cancer? David Tuveson, Cambridge
16.20 - 16.40	14. Fluorescence imaging to detect PanIN lesions Dieter Saur, Munich
16.40 - 17.00	15. Practical experience with detection of precancerous lesions in high risk groups in a clinical setting.Marcia Canto, Baltimore
17.00	Concluding Remarks, Farewells

Note: all listed speakers have confirmed their participation.

Draft, status: 16.02.2012